Food and Drug Administration (FDA) for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition
Choosing quality care over the absolute cheapest option ensures you receive safe medications and proper medical supervision
A favorite for events, photoshoots, or anyone craving that hydrated, radiant look
Above 10 g/day GI side effects rise sharply with little added benefit
Week 1 to 2: Redness subsides
While it is believed that semaglutide leads to gastrointestinal disorders less than 5% of the time, transient, mild-to-moderate bouts of the following issues are commonplace among GLP-1 drugs: Nausea : 44% Vomiting: 25% Diarrhea: 32% Constipation: 23% Abdominal pain: 10% Fatigue, Dizziness, Headache Clinical data does not support the idea that semaglutide directly causes dizziness, headaches, or significant fatigue